VESIcare LS™ (solifenacin succinate) – New drug approval
May 26, 2020 - The FDA announced the approval of Astellas’ VESIcare LS (solifenacin succinate) oral suspension, for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 2 years and older.
Download PDF
